A General Strategy for the Synthesis of Rare Sugars via Ru(II)-catalyzed and Boron-mediated Selective Epimerization of 1,2-trans-diols to 1,2-cis-diols

27 December 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Human glycans are primarily composed of nine common sugar building blocks. On the other hand, several hundred monosaccharides have been discovered in bacteria and most of them are not readily available. The ability to access these rare sugars and the corresponding glycocon-jugates can facilitate the studies of various fundamentally important biological processes in bacteria, including interactions between microbiota and the human host. Many rare sugars also exist in a variety of natural products and pharmaceutical reagents with significant biological activi-ties. Although methods have been developed for the synthesis of rare monosaccharides, most of them involve lengthy steps. Herein we report an efficient and general strategy that can provide access to rare sugars from commercially available common monosaccharides via a one-step Ru(II)-catalyzed and boron-mediated selective epimerization of 1,2-trans-diols to 1,2-cis-diols. The formation of boronate esters drives the equilibrium towards 1,2-cis-diol products, which can be immediately used for further selective functionalization and glycosylation. The utility of this strategy was demonstrated by the efficient construction of glycoside skeletons in natural products or bioactive compounds.

Keywords

carbohydrate
organometallic
catalysis
ruthenium
boron
diol
isomerization
epimerization
rare sugar

Supplementary materials

Title
Description
Actions
Title
SI
Description
supporting information
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.